Combinedtreatment with amisulpride in patients with schizophrenia discharged from a short-term hospitalization unit: A 1-year retrospective study

Clinical Neuropharmacology

Volumn 32, Issue 1, 2009, Pages 10-15

  Molina, Juan D ^a   Lerma Carrillo, Iván ^a   Leonor, Marta ^a   Pascual, Fernando ^a   Blasco Fontecilla, Hilario ^a   González Parra, Silvia ^a   López Muñoz, Francisco ^b   Alamo, Cecilio ^b  

^a Hospital Dr Rodríguez Lafora   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Amisulpride; Antipsychotics; Polypharmacy; Schizoaffective disorder; Schizophrenia

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; BENZODIAZEPINE DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DRUG DERIVATIVE; NEUROLEPTIC AGENT; SULPIRIDE; SULTOPRIDE;

ADD ON THERAPY; ADULT; ARTICLE; FEMALE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MONOTHERAPY; PARANOID SCHIZOPHRENIA; POLYPHARMACY; PRESCRIPTION; PRIORITY JOURNAL; RESIDUAL SCHIZOPHRENIA; RETROSPECTIVE STUDY; SCHIZOAFFECTIVE PSYCHOSIS; CLINICAL TRIAL; DRUG COMBINATION; HOSPITAL DISCHARGE; MIDDLE AGED; PSYCHOSIS; SCHIZOPHRENIA; STATISTICS;

ADULT; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; CHOLINERGIC ANTAGONISTS; DRUG THERAPY, COMBINATION; FEMALE; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PATIENT DISCHARGE; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; SULPIRIDE;

EID: 67749116336     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/WNF.0b013e3181672213     Document Type: Article

References (46)

1. Kane JM, Leucht S, Carpenter D, et al. Expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders. Introduction: methods, commentary, and summary. J Clin Psychiatry 2003;64:5-19.
2. Lehman AF, Lieberman JA, Dixon LB, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56.
3. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004;30:193-217.
4. Miller AL, Crismon ML, Rush AJ, et al. The Texas medication algorithm project: clinical results for schizophrenia. Schizophr Bull 2004;30:627-647.
5. National Institute for Mental Health in England. Schizophrenia. Implementing NICE Guidance: an interactive implementation resource tool. Available at: http://www.schizophreniaguidelines.co.uk/. Accessed March 23, 2007.
6. Kane JM. The current status of neuroleptic therapy. J Clin Psychiatry 1989;50:322-328.
7. Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic patients. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988;45:789-796.
8. Juul PU, Noring U, Fog R, et al. Tolerability and therapeutic effect of clozapine. A retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 1985;71:176-185.
9. Tapp A, Wood AE, Secrest L, et al. Combination antipsychotic therapy in clinical practice. Psychiatric Serv 2003;54:55-59.
10. Heresco-Levy U, Greenberg D, Wittman L, et al. Prescribing patterns of neuroactive drugs in 98 schizophrenic patients. Isr J Psychiatry Relat Sci 1989;26:157-163.
11. Kiivet RA, Llerena A, Dahl ML, et al. Patterns of drug treatment of schizophrenic patients in Estonia, Spain and Sweden. Br J Clin Pharmacol 1995;40:467-476.
12. Ungvari GS, Pang AH, Chiu HF, et al. Psychotropic drug prescription in rehabilitation. A survey in Hong Kong. Soc Psychiatry Psychiatr Epidemiol 1996;31:288-291.
13. Ito C, Kubota Y, Sato M. A prospective survey on drug choice for prescriptions for admitted patients with schizophrenia. Psychiatry Clin Neurosci 1999;53:S35-S40.
14. Rittmannsberger H, Meise U, Schauflinger K, et al. Polypharmacy in psychiatric treatment. Patterns of psychotropic drug use in Austrian psychiatric clinics. Eur Psychiatry 1999;14:33-40.
15. Wang PS, West JC, Tanielian T, et al. Recent patterns and predictors of antipsychotic medication regimens used to treat schizophrenia and other psychotic disorders. Schizophr Bull 2000;26:451-457.
16. Fourrier A, Gasquet I, Allicar MP, et al. Patterns of neuroleptic drug prescription: a national cross-sectional survey of a random sample of French psychiatrists. Br J Clin Pharmacol 2000;49:80-86.
17. Procyshyn RM, Kennedy NB, Tse G, et al. Antipsychotic polypharmacy: a survey of discharge prescriptions from a tertiary care psychiatric institution. Can J Psychiatry 2001;46:334-339.
18. Weissman EM. Antipsychotic prescribing practices in the Veterans Healthcare Administration-New York metropolitan region. Schizophr Bull 2002;28:31-42.
19. Covell NH, Jackson CT, Evans AC, et al. Antipsychotic prescribing practices in Connecticut's public mental health system: rates of changing medications and prescribing styles. Schizophr Bull 2002;28:17-29.
20. Clark RE, Bartels SJ, Mellman TA, et al. Recent trends in antipsychotic combination therapy of schizophrenia and schizoaffective disorder: implications for state mental health policy. Schizophr Bull 2002;28:75-84.
21. McCue RE, Waheed R, Urcuyo L. Polypharmacy in patients with schizophrenia. J Clin Psychiatry 2003;64:984-989.
22. Flórez-Menéndez MG, Blanco RM, Gómez-Reino R, et al. Polifarmacia en la prescripción de antipsícóticos en consultas de psiquiatría. Actas Esp Psiquiatr 2004;32:333-339.
23. Ganguly R, Kotzan JA, Miller LS, et al. Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. J Clin Psychiatry 2004;65:1377-1388.
24. Sim K, Su A, Fujii S, et al. Antipsychotic polypharmacy in patients with schizophrenia: a multicentre comparative study in East Asia. Br J Clin Pharmacol 2004;58:178-183.
25. Janssen B, Weinmann S, Berger M, et al. Validation of polypharmacy process measures in inpatient schizophrenia care. Schizophr Bull 2004;30:1023-1033.
26. Faries D, Ascher-Svanum H, Zhu B, et al. Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics. BMC Psychiatry 2005;5:26. Available at: http://www.biomedcentral.com/1471-244X/5/26.
27. Ito H, Koyama A, Higuchi T. Polypharmacy and excessive dosing: psychiatrists' perceptions of antipsychotic drug prescription. Br J Psychiatry 2005;187:243-247.
28. Lerma-Carrillo I, Leonor del Pozo M, Pascual-Pinazo F, et al. Polypharmacy and prescribing patterns in patients with schizophrenia in an acute unit in Spain. Schizophr Bull 2007;33:475.
29. Shiloh R, Zemishlany Z, Aizenberg D, et al. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study. Br J Psychiatry 1997;171:569-573.
30. Anil Yagcioglu AE, Kivircik Akdede BB, Turgut TI, et al. A double-blind controlled study of adjunctive treatment with risperidone in schizophrenic patients partially responsive to clozapine: efficacy and safety. J Clin Psychiatry 2005;66:63-72.
31. Josiassen RC, Joseph A, Kohegyi E, et al. Clozapine augmented with risperidone in the treatment of schizophrenia: a randomized, double-blind, placebo-controlled trial. Am J Psychiatry 2005; 162:130-136.
32. Honer WG, Thornton AE, Chen EY, et al. Clozapine alone versus clozapine and risperidone with refractory schizophrenia. N Engl J Med 2006;354:472-482.
33. Agelink MW, Kavuk I, Ak I. Clozapine with amisulpride for refractory schizophrenia. Am J Psychiatry 2004;161:924-925.
34. Cook B, Hoogenboom G. Combined use of amisulpride and clozapine for patients with treatment-resistant schizophrenia. Australas Psychiatry 2004;12:74-76.
35. Munro J, Matthiasson P, Osborne S, et al. Amisulpride augmentation of clozapine: an open non-randomized study in patients with schizophrenia partially responsive to clozapine. Acta Psychiatr Scand 2004;110:292-298.
36. Zink M, Henn FA, Thome J. Combination of amisulpride and olanzapine in treatment-resistant schizophrenic psychoses. Eur Psychiatry 2004;19:56-58.
37. Zink M, Knopf U, Henn FA, Thome J. Combination of clozapine and amisulpride in treatment-resistant schizophrenia - case reports and review of the literature. Pharmacopsychiatry 2004;37:26-31.
38. George S, Cowan C. Effectiveness of amisulpride augmentation of clozapine in a non-responder to either drug alone: a case report. Acta Psychiatr Scand 2005;111:163.
39. Kämpf P, Agelink MW, Naber D. Augmentation of clozapine with amisulpride: a promising therapeutic approach to refractory schizophrenic symptoms. Pharmacopsychiatry 2005;38:39-40.
40. Lerner V, Bergman J, Borokhov A, et al. Augmentation with amisulpride for schizophrenic patients nonresponsive to antipsychotic monotherapy. Clin Neuropharmacol 2005;28:66-71.
41. Kreinin A, Novitski D, Weizman A. Amisulpride treatment of clozapine-induced hypersalivation in schizophrenia patients: a randomized, double-blind, placebo-controlled cross-over study. Int Clin Psychopharmacol 2006;21:99-103.
42. Leucht S. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials. Int J Neuropsychopharmacol 2004;7:S15-S20.
43. Kissling W. Compliance, quality management and standards in the treatment of schizophrenia. Neuropsychobiology 1997;35:70-72.
44. Freudenreich O, Goff DC. Antipsychotic combination therapy in schizophrenia. A review of efficacy and risks of current combinations. Acta Psychiatr Scand 2002;106:323-330.
45. Stahl S. Antipsychotic agents. In: Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. 2nd ed. Cambridge, MA: Cambridge University Press, 2000:401-458.
46. National Association of State Mental Health Program Directors, Medical Directors Council and State Medicaid Directors. NASMHPD Medical Directors' Technical Report on Psychiatric Polypharmacy. Alexandria, VA: NASMHPD Research Institute, Inc, 2001.